Trial Profile
A Single-Sequence, Open-Label, 2-Period, Crossover Trial to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Single-Dose Pharmacokinetics of Oral TAK-906 in Healthy Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Trazpiroben (Primary) ; Itraconazole
- Indications Gastroparesis
- Focus Pharmacokinetics
- Sponsors Takeda Oncology
- 24 Oct 2018 Results presented at the 26th United European Gastroenterology Week
- 13 Jul 2017 Status changed to completed.
- 26 May 2017 New trial record